Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zeneca launches cancer diagnostic kit:

This article was originally published in Clinica

Executive Summary

Uk-based Zeneca Diagnostics has launched its first cancer diagnostic kit, Elucigene K-RAS7, in Europe. The test detects the seven most common mutations in the K-ras proto-oncogene, found in the DNA of many types of cancer cells - including bowel, pancreatic and lung cancer. Zeneca claims the test is sufficiently sensitive to spot K-ras mutations even in samples containing predominantly normal tissue. It can thus give early warning of malignancy as well as typing and monitoring of known tumours. The kit is the fourth in the Elucigene series.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT081351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel